GoAI
Get started
Entrada Therapeutics, Inc. logo

Entrada Therapeutics, Inc.

TRDA

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$7.57

−$0.03 · -0.39%

Aug 21, 4:00 PM ET

TRDA company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

20

Overpriced

Momentum

22

Weakening

Sentiment

68

Bullish

Risk resilience

37

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs, integrating oligonucleotide, antibody, and enzyme-based approaches. Its foremost product candidate, ENTR-601-44, is currently undergoing preclinical assessment for its potential in addressing both Duchenne muscular dystrophy and myotonic dystrophy type 1. Furthermore, Entrada is actively developing EEV-PMO-CAG, also targeting myotonic dystrophy type 1. Incorporated in 2016, the firm was formerly known as CycloPorters, Inc., before officially changing its name to Entrada Therapeutics, Inc. in October 2017. The company maintains its corporate headquarters in Boston, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Dipal Doshi
Listed since
Oct 29, 2021
Employees
152

Market position

Day range

Current $7.57

52-week range

Current $7.57

Open
$7.65
Previous close
$7.60
Volume
141.02K
0.34× average
Average volume
413.47K
Average daily volume
Market cap
293.87M USD
Beta
-0.26
Market reference 1
50-day average
$7.0007
+8.13% above average
200-day average
$9.6928
-21.90% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
385.84M USD
P/E (TTM)
-1.91×
P/B (TTM)
1.37×
P/S (TTM)
62.71×
EV / EBITDA
-2.71×
Earnings yield
-33.80%
Free cash flow yield
-30.46%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
-754.72%
Operating margin
-3767.07%
Net margin
-3537.73%
Return on equity
-46.96%
Return on assets
-38.09%
Return on invested capital
-43.69%

Financial health

Debt / equity
0.21×
Current ratio
12.53×
Altman Z-score
0.07
Piotroski F-score
1 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends171%-114%-400%-685%Gross margin, FY2023: 100.00%Gross margin, FY2024: 100.00%Gross margin, FY2025: 83.89%Operating margin, FY2023: -2.45%Operating margin, FY2024: 22.30%Operating margin, FY2025: -613.66%Net margin, FY2023: -5.18%Net margin, FY2024: 31.13%Net margin, FY2025: -565.48%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2023 100.00%. Gross margin FY2024 100.00%. Gross margin FY2025 83.89%. Operating margin FY2023 -2.45%. Operating margin FY2024 22.30%. Operating margin FY2025 -613.66%. Net margin FY2023 -5.18%. Net margin FY2024 31.13%. Net margin FY2025 -565.48%.

Income trends

Revenue

25.42M USD-87.94%

Operating income

−156M USD−203.01M USD

Net income

−143.75M USD−209.38M USD
Income trends across reported periods247.46M USD100.75M USD−45.96M USD−192.68M USDRevenue, FY2023: 129.01M USDRevenue, FY2024: 210.78M USDRevenue, FY2025: 25.42M USDOperating income, FY2021: −51.13M USDOperating income, FY2022: −97.25M USDOperating income, FY2023: −3.16M USDOperating income, FY2024: 47.01M USDOperating income, FY2025: −156M USDNet income, FY2021: −51.16M USDNet income, FY2022: −94.62M USDNet income, FY2023: −6.69M USDNet income, FY2024: 65.63M USDNet income, FY2025: −143.75M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2023 129.01M USD. Revenue FY2024 210.78M USD. Revenue FY2025 25.42M USD. Operating income FY2021 −51.13M USD. Operating income FY2022 −97.25M USD. Operating income FY2023 −3.16M USD. Operating income FY2024 47.01M USD. Operating income FY2025 −156M USD. Net income FY2021 −51.16M USD. Net income FY2022 −94.62M USD. Net income FY2023 −6.69M USD. Net income FY2024 65.63M USD. Net income FY2025 −143.75M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue25.42M USD210.78M USD129.01M USD——
Cost of goods sold4.1M USD————
Gross profit21.33M USD210.78M USD129.01M USD——
Research and development142.27M USD125.31M USD99.88M USD66.61M USD35.93M USD
Selling, general, and administrative41.05M USD38.47M USD32.29M USD30.64M USD15.2M USD
Operating expenses177.32M USD163.77M USD132.18M USD97.25M USD51.13M USD
Interest income—19.47M USD15.22M USD2.63M USD—
Interest expense———2.63M USD—
Depreciation and amortization425K USD3.77M USD2.84M USD1.9M USD1.12M USD
Operating income−156M USD47.01M USD−3.16M USD−97.25M USD−51.13M USD
Net income−143.75M USD65.63M USD−6.69M USD−94.62M USD−51.16M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
64%
7 beats, 4 misses, 0 met estimates
Average EPS surprise
+101.74%
11 comparable reports
Latest EPS result
-1.01
Estimate -0.97 · Miss by 3.72%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.14-0.38-0.91-1.43Q1 '25BeatQ2 '25BeatQ3 '25MissQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Feb 27, 2025: actual 0.03, estimate -0.66, surprise +104.55%, Beat. Q2 2025, reported May 8, 2025: actual -0.42, estimate -0.78, surprise +46.15%, Beat. Q3 2025, reported Aug 6, 2025: actual -1.04, estimate -0.86, surprise -20.93%, Miss. Q4 2025, reported Nov 6, 2025: actual -1.06, estimate -1.04, surprise -1.92%, Miss. Q1 2026, reported Feb 26, 2026: actual -0.94, estimate -1.32, surprise +28.79%, Beat. Q2 2026, reported May 7, 2026: actual -0.95, estimate -1.06, surprise +10.38%, Beat. Q3 2026, reported Aug 5, 2026: actual -1.01, estimate -0.974, surprise -3.72%, Miss. Q4 2026, reported Nov 5, 2026: actual —, estimate -0.98, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates40.32M27.13M13.94M743.75KQ1 '25BeatQ2 '25BeatQ3 '25MissQ4 '25MissQ1 '26MissQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Feb 27, 2025: actual 37.4M USD, estimate 13.12M USD, surprise +185.04%, Beat. Q2 2025, reported May 8, 2025: actual 20.56M USD, estimate 9.77M USD, surprise +110.40%, Beat. Q3 2025, reported Aug 6, 2025: actual 1.95M USD, estimate 7.83M USD, surprise -75.11%, Miss. Q4 2025, reported Nov 6, 2025: actual 1.61M USD, estimate 8.49M USD, surprise -80.99%, Miss. Q1 2026, reported Feb 26, 2026: actual 1.3M USD, estimate 7.41M USD, surprise -82.47%, Miss. Q2 2026, reported May 7, 2026: actual 875K USD, estimate 2.92M USD, surprise -70.03%, Miss. Q3 2026, reported Aug 5, 2026: actual 898K USD, estimate 2.32M USD, surprise -61.37%, Miss. Q4 2026, reported Nov 5, 2026: actual —, estimate 2.13M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$14.00

84.94% upside
Past 12 months12-month forecastHigh $17.00Average $14.00Low $11.00

Rating distribution

6 ratings
Strong buy00%
Buy467%
Hold233%
Sell00%
Strong sell00%

Recent analyst actions

3 institutions
GuggenheimmaintainBuy

TRDA news

zacks.com

Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Tops Revenue Estimates

Entrada Therapeutics, Inc. (TRDA) came out with a quarterly loss of $1.01 per share versus the Zacks Consensus Estimate of a loss of $1.16. This compares to a loss of $1.04 per share a year ago.

Read source
globenewswire.com

Entrada Therapeutics Reports Second Quarter 2026 Financial Results

-- Company to report ELEVATE-44-201 data from Cohort 1 open-label period by year-end 2026 -- -- ELEVATE-44-201 Cohort 2 enrollment complete with data expected in Q1 2027 -- -- Company to report ELEVATE-45-201 Cohort 1…

Read source
seekingalpha.com

Entrada Therapeutics, Inc. (TRDA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Entrada Therapeutics, Inc. (TRDA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Read source
prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA

NEW YORK, June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Entrada Therapeutics, Inc. ("Entrada" or the "Company") (NASDAQ: TRDA). Such investors are advised to contact…

Read source
globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA

NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Entrada Therapeutics, Inc. (“Entrada” or the “Company”) (NASDAQ: TRDA). Such investors are advised to contact…

Read source
globenewswire.com

Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study

-- Participants in Cohort 1 have progressed to the open-label, Phase 2 portion of ELEVATE-45-201 -- -- Company on track to report ELEVATE-45-201 Cohort 1 data in mid-2026 -- BOSTON, June 02, 2026 (GLOBE NEWSWIRE) --…

Read source

TRDA peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding TRDA

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
6.48M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
5.75M
Weight
0.01%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
iShares Russell 2000 Value ETF logoiShares Russell 2000 Value ETFIWN
Market value
2.05M
Weight
0.01%
AUM
14.66B USD
Expense ratio
0.24%
Price / 1D
$224.81+0.45%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
1.92M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
1.21M
Weight
0.01%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$213.56+1.29%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
1.13M
Weight
0.01%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
Schwab U.S. Small-Cap ETF logoSchwab U.S. Small-Cap ETFSCHA
Market value
860.28K
Weight
0.00%
AUM
23.1B USD
Expense ratio
0.03%
Price / 1D
$34.83+0.52%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
777.31K
Weight
0.05%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%

Continue in GoAI

Research TRDA

research.disclaimer